Xolair (omalizumab)

pCPA File Number: 20944

Negotiation Status:

Concluded without agreement

Indication(s):

Severe Persistent Asthma

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

SR0457-000

pCPA Engagement Letter Issued:

2016-10-21

Negotiation Process Concluded:

2019-06-25